A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation
Clinical trial NCT07229846 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07229846
- Sponsor
- Yanqiao Zhang
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-02-01
- Primary completion
- 2027-02-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.